GWLL
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. The company is developing five products, including JI MAI—bovine cardiac vascular active peptide; cartilage peptide, a type II collagen peptide; and Double Proline AG 3D active collagen peptide, as well as DNA repair tablets and sugar master tablets. The company was incorporated in 2019 and is based in Twinsburg, Ohio.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.00 | $25,000 | -$30,885 |
| 2025 Q2 | -0.00 | $37,500 | $59,381 |
| 2025 Q1 | -0.00 | $0 | -$32,277 |
| 2024 Q4 | -0.00 | -$158 | -$19,051 |
| 2024 Q3 | -0.00 | $0 | -$23,065 |
| 2024 Q2 | -0.00 | $139 | -$49,851 |
| 2024 Q1 | -0.00 | $158 | -$31,110 |
| 2023 Q4 | -0.00 | $260 | -$20,612 |